Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis.

Patients with greater clinical improvement after 8 weeks of tofacitinib induction therapy are more likely to maintain response or remission with tofacitinib regardless of dose received during maintenance, highlighting the importance of a robust response to induction therapy.